Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets liver damage in rare genetic disease

NCT ID NCT03946449

Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called fazirsiran in 16 people with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver damage. The drug aims to reduce harmful protein buildup in the liver. Researchers measured changes in liver protein levels and safety over 24 to 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fazirsiran (also called TAK-999 or ARO-AAT)
What this could lead to
If it works, this could point toward a treatment that reduces harmful protein buildup in the liver for people with alpha-1 antitrypsin deficiency.
What could go wrong
This is a small, early-phase trial with only 16 participants, so results may not apply to everyone. The drug may not show enough benefit or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

16 people

The number who actually took part.

Started

Oct 2019

Finished

Dec 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of AATD * Liver biopsy indicating Metavir F1-F3 liver fibrosis based on local pathology read. * Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use contraception * Willing to provide written informed consent and to comply with study requirements * Non-smoker for at least 1 year * No abnormal finding of clinical relevance at screening Exclusion Criteria: * Clinically significant health concerns other than AATD * Previous diagnosis or diagnosis at Screening of definitive liver cirrhosis * Regular use of alcohol within one month prior to Screening * Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study involving therapeutic intervention * Use of illicit drugs within 1 year prior to Screening Note: additional inclusion/exclusion criteria may apply, per protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alpha 1 antitrypsin deficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alpha 1 antitrypsin deficiency

Contacts and locations

Locations

  • Research Center 1

    Vienna, 1090, Austria

  • Research Center 1

    Aachen, 52074, Germany

  • Research Center 2

    Edinburgh, EH19 3BJ, United Kingdom

  • Research Center 3

    Cambridge, CB2 0QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.